title: Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.
abstract: OBJECTIVE
  To investigate the use of pretreatment carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) as prognostic factors to determine survival in pancreatic adenocarcinoma.
  
  
  METHODS
  A retrospective review of the medical records of patients who were diagnosed with pancreatic adenocarcinoma and received surgery, chemoradiotherapy or chemotherapy was performed. Factors, including CA 19-9 and CEA, associated with the survival of pancreatic cancer patients were analyzed.
  
  
  RESULTS
  Patients with the median age of 65 years were included (n=187). Elevated serum CA 19-9 levels and CEA levels were observed in 75.4% and 39% of patients at diagnosis, respectively. CEA was correlated with tumor stages (p=0.005), but CA 19-9 was not. CA 19-9 and CEA were elevated in 69.0% and 33.3% of patients with resectable pancreatic cancer, and elevated in 72.9% and 47.2% of patients with advanced pancreatic cancer, respectively. The median overall survival of the normal serum CEA group was longer than that of the elevated serum CEA group (16.3 months vs. 10.2 months, p=0.004). However, the median overall survival of the normal serum CA 19-9 group was not different from that of the elevated serum CA 19-9 group (12.4 months vs. 13.5 months, p=0.969). The independent factors associated with overall survival were advanced pancreatic cancer [harzard ratio (HR) 4.33, p=0.001] and elevated serum CEA level (HR 1.52, p=0.032).
  
  
  CONCLUSIONS
  Patients with elevated serum CEA level at diagnosis demonstrated poor overall survival. Pretreatment CEA level may predict the prognosis of patients with pancreatic adenocarcinoma.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
authors.forename: Kyong Joo
authors.initials: KJ
authors.lastname: Lee
authors.forename: Seung Woo
authors.initials: SW
authors.lastname: Yi
authors.forename: Moon Jae
authors.initials: MJ
authors.lastname: Chung
authors.forename: Seung Woo
authors.initials: SW
authors.lastname: Park
authors.forename: Si Young
authors.initials: SY
authors.lastname: Song
authors.forename: Jae Bock
authors.initials: JB
authors.lastname: Chung
authors.forename: Jeong Youp
authors.initials: JY
authors.lastname: Park
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen; C578959:carbohydrate antigen 199, human
keywords: CA 19-9; carcinoembryonic antigen; pancreas adenocarcinoma; prognosis
references.citation: Am J Surg. 1990 May;159(5):454-6
references.pmid: 2334005
references.citation: Minerva Chir. 2004 Apr;59(2):99-111
references.pmid: 15238885
references.citation: Cancer. 1978 Sep;42(3 Suppl):1468-71
references.pmid: 709516
references.citation: J Cancer Res Clin Oncol. 2011 Mar;137(3):375-89
references.pmid: 21193998
references.citation: J Exp Med. 1965 Mar 1;121:439-62
references.pmid: 14270243
references.citation: J Clin Oncol. 2008 Dec 20;26(36):5918-22
references.pmid: 19029412
references.citation: Int J Gastrointest Cancer. 2002;32(1):35-41
references.pmid: 12630768
references.citation: Cancer Res. 1987 Oct 15;47(20):5501-3
references.pmid: 3308077
references.citation: Pancreas. 1994 Nov;9(6):735-40
references.pmid: 7846017
references.citation: Br J Surg. 2008 Apr;95(4):453-9
references.pmid: 18161888
references.citation: Eur J Surg Oncol. 1992 Oct;18(5):508-13
references.pmid: 1426303
references.citation: Eur J Surg Oncol. 2005 Mar;31(2):164-9
references.pmid: 15698733
references.citation: Gynecol Oncol. 1995 May;57(2):205-11
references.pmid: 7729735
references.citation: Trop Gastroenterol. 2010 Jul-Sep;31(3):190-4
references.pmid: 21560524
references.citation: Schweiz Med Wochenschr. 1999 Jan 23;129(3):77-9
references.pmid: 10065510
references.citation: Lung Cancer. 2012 May;76(2):138-43
references.pmid: 22153832
references.citation: CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
references.pmid: 21685461
references.citation: Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1148-54
references.pmid: 18760544
references.citation: Tumour Biol. 2010 Jun;31(3):171-80
references.pmid: 20361287
references.citation: Lancet Oncol. 2008 Feb;9(2):132-8
references.pmid: 18249033
references.citation: Clin Cancer Res. 2008 Aug 1;14(15):4843-9
references.pmid: 18676757
references.citation: Expert Opin Biol Ther. 2011 Nov;11(11):1409-18
references.pmid: 21871012
references.citation: Dis Colon Rectum. 1999 Jul;42(7):921-9
references.pmid: 10411440
references.citation: J Gastroenterol Hepatol. 2009 Dec;24(12):1869-75
references.pmid: 19686409
references.citation: Science. 1981 Apr 3;212(4490):53-5
references.pmid: 6163212
references.citation: Cell. 1989 Apr 21;57(2):327-34
references.pmid: 2702691
references.citation: Eur J Surg Oncol. 2007 Apr;33(3):266-70
references.pmid: 17097848